Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced its upcoming participation in two major healthcare investor conferences this March. Richard Francis, Teva's President and CEO, will be presenting at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025, at 8:00 am ET, followed by the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET.
Investors and interested parties can access live webcasts of both presentations through Teva's Investor Relations website. Archived versions will be made available within 24 hours after each live discussion concludes.
Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori nel settore della salute questo marzo. Richard Francis, Presidente e CEO di Teva, presenterà alla 27a Conferenza Globale Annuale sulla Salute di Barclays martedì 11 marzo 2025, alle 8:00 ET, seguita dalla Conferenza Globale sulla Salute di Leerink Partners mercoledì 12 marzo 2025, alle 8:40 ET.
Gli investitori e le parti interessate possono accedere alle dirette streaming di entrambe le presentazioni attraverso il sito web delle Relazioni con gli Investitori di Teva. Versioni archiviate saranno rese disponibili entro 24 ore dalla conclusione di ciascuna discussione dal vivo.
Teva Pharmaceutical Industries (NYSE y TASE: TEVA) ha anunciado su próxima participación en dos importantes conferencias de inversores en el sector salud este marzo. Richard Francis, Presidente y CEO de Teva, presentará en la 27ª Conferencia Global Anual de Salud de Barclays el martes 11 de marzo de 2025, a las 8:00 am ET, seguida de la Conferencia Global de Salud de Leerink Partners el miércoles 12 de marzo de 2025, a las 8:40 am ET.
Los inversores y partes interesadas pueden acceder a las transmisiones en vivo de ambas presentaciones a través del sitio web de Relaciones con Inversores de Teva. Las versiones archivadas estarán disponibles dentro de las 24 horas posteriores a la conclusión de cada discusión en vivo.
테바 제약 산업 (NYSE 및 TASE: TEVA)은 이번 3월 두 개의 주요 헬스케어 투자자 회의에 참여할 것이라고 발표했습니다. 리차드 프랜시스, 테바의 사장 겸 CEO는 2025년 3월 11일 화요일 오전 8시(ET)에 바클레이스 제27회 글로벌 헬스케어 컨퍼런스에서 발표할 예정이며, 이어서 2025년 3월 12일 수요일 오전 8시 40분(ET)에 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다.
투자자 및 관심 있는 당사자들은 테바의 투자자 관계 웹사이트를 통해 두 발표의 생중계를 시청할 수 있습니다. 각 생중계가 종료된 후 24시간 이내에 아카이브된 버전이 제공될 예정입니다.
Teva Pharmaceutical Industries (NYSE et TASE : TEVA) a annoncé sa participation prochaine à deux grandes conférences pour investisseurs dans le secteur de la santé ce mois de mars. Richard Francis, Président et CEO de Teva, présentera à la 27ème Conférence Annuelle Mondiale sur la Santé de Barclays le mardi 11 mars 2025, à 8h00 ET, suivie de la Conférence Mondiale sur la Santé de Leerink Partners le mercredi 12 mars 2025, à 8h40 ET.
Les investisseurs et les parties intéressées peuvent accéder aux diffusions en direct des deux présentations via le site Web des Relations avec les Investisseurs de Teva. Des versions archivées seront mises à disposition dans les 24 heures suivant la fin de chaque discussion en direct.
Teva Pharmaceutical Industries (NYSE und TASE: TEVA) hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitswesen im März angekündigt. Richard Francis, Präsident und CEO von Teva, wird am Dienstag, den 11. März 2025, um 8:00 Uhr ET auf der 27. jährlichen globalen Gesundheitskonferenz von Barclays präsentieren, gefolgt von der globalen Gesundheitskonferenz von Leerink Partners am Mittwoch, den 12. März 2025, um 8:40 Uhr ET.
Investoren und Interessierte können die Live-Übertragungen beider Präsentationen über die Investor-Relations-Website von Teva verfolgen. Archivierte Versionen werden innerhalb von 24 Stunden nach Abschluss jeder Live-Diskussion verfügbar sein.
- None.
- None.
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in March as follows:
- Barclays 27th Annual Global Healthcare Conference
Tuesday, March 11, 2025, at 8:00 am ET - Leerink Partners Global Healthcare Conference
Wednesday, March 12, 2025, at 8:40 am ET
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we’re already working to address it. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com

FAQ
When is Teva (TEVA) presenting at the Barclays Global Healthcare Conference in 2025?
What time is Teva's (TEVA) presentation at the Leerink Partners Conference in March 2025?
How can investors access Teva's (TEVA) March 2025 healthcare conference presentations?
When will the recordings of Teva's (TEVA) March 2025 conference presentations be available?